MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Book Value 2011-2026 | TMO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 B | 97.3 B | 98.7 B | 97.2 B | 95.1 B | 69.1 B | 29.7 B | 27.6 B | 25.4 B | 21.5 B | 21.4 B | 20.5 B | 16.9 B | 15.5 B | 15 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 B | 15 B | 50.7 B |
Quarterly Book Value Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103 B | 101 B | 99 B | 100 B | 98.5 B | 97.1 B | 97.1 B | 94.1 B | 94.7 B | 97.2 B | 90.5 B | - | 92.7 B | 95.1 B | 73.6 B | 67.7 B | 65.9 B | 69.1 B | 69.1 B | 69.1 B | 69.1 B | 58.4 B | 58.4 B | 58.4 B | 58.4 B | 56.2 B | 56.2 B | 56.2 B | 56.2 B | 56.7 B | 56.7 B | 56.7 B | 56.7 B | 45.9 B | 45.9 B | 45.9 B | 45.9 B | 40.8 B | 40.8 B | 40.8 B | 40.8 B | 42.9 B | 42.9 B | 42.9 B | 42.9 B | 31.9 B | 31.9 B | 31.9 B | 31.9 B | 27.4 B | 27.4 B | 27.4 B | 27.4 B | 26.8 B | 26.8 B | 26.8 B | 26.8 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 103 B | 26.8 B | 58.8 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.39 B | - | - | $ 34.8 B |  USA |
 |
Celcuity
CELC
|
101 M | $ 138.31 | -2.96 % | $ 6.47 B | USA |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 3.64 | -1.84 % | $ 4.84 M | USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
471 M | $ 20.25 | -1.44 % | $ 587 M | USA |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.92 | -2.65 % | $ 512 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 118.39 | 0.32 % | $ 14.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
303 M | $ 21.28 | -1.34 % | $ 1.13 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 115.85 | -0.62 % | $ 9.56 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M |  Israel |
 |
Illumina
ILMN
|
6.3 B | $ 144.62 | -0.15 % | $ 23 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 94.61 | 0.14 % | $ 6.39 B | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 424.73 | -1.25 % | $ 12.3 B | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 156.61 | -1.46 % | $ 7.76 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 092.76 | 0.21 % | $ 22.5 B |  Schweiz |
 |
NeoGenomics
NEO
|
837 M | $ 9.1 | -0.11 % | $ 1.17 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 18.85 | -1.0 % | $ 422 M | USA |
 |
Natera
NTRA
|
706 M | - | - | $ 20.1 B | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 3.81 | -2.69 % | $ 353 M | USA |
 |
Personalis
PSNL
|
261 M | $ 8.2 | -0.67 % | $ 732 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.12 | -0.07 % | $ 25.7 B |  Niderland |
 |
Senseonics Holdings
SENS
|
61 M | $ 6.43 | 4.38 % | $ 268 M | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
450 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.39 | -2.05 % | $ 5.49 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 258.32 | 1.08 % | $ 21.5 B | USA |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 59.88 | 1.77 % | $ 3.58 B | USA |
 |
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.61 | -2.45 % | $ 219 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 8.98 | 1.3 % | $ 1.95 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 194.74 | 0.47 % | $ 21.6 B | USA |
 |
Waters Corporation
WAT
|
2.56 B | $ 339.43 | -0.46 % | $ 20.2 B | USA |